Price
CHART BY
Frequently asked questions
What is Regulus's market capitalization?
What is the Earnings Per Share (EPS) for Regulus?
What are the analyst ratings and target price for Regulus's stock?
What is the EBITDA for Regulus?
What is the free cash flow of Regulus?
How many employees does Regulus have, and what sector and industry does it belong to?
What is the free float of Regulus's shares?
Financials
- Market Cap
- $136.46M
- EPS (TTM)
- -$0.876
- Free Float
- 53.18M
- EBITDA (TTM)
- -$49.70M
- Free Cashflow (TTM)
- -$42.01M
Pricing
- 1D span
- $1.906$2.094
- 52W span
- $0.832$2.90
Analyst Ratings
The price target is $10.83 and the stock is covered by 6 analysts.
Buy
6
Hold
0
Sell
0
Information
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
- Employees
- 34
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US75915K3095
- Primary Ticker
- RGLS